(Press-News.org) Washington D.C., January 9, 2012 - While pharmacologic agents have a demonstrated efficacy in children with Attention-deficit/hyperactivity disorder (ADHD), some children have suboptimal response to a single pharmacologic agent. A recent study by Dr. Timothy E. Wilens and colleagues, published in the January 2012 issue of the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP), is the first randomized placebo-controlled trial designed to assess efficacy and safety of guanfacine extended release (GXR) as an adjunct to psychostimulants in children and adolescents diagnosed with ADHD who had a suboptimal response to a psychostimulant alone.
As reported in the article "A Controlled Trial of Extended-release Guanfacine and Psychostimulants for Attention-deficit/hyperactivity disorder," Wilens and colleagues conducted a nine week multicenter, double-blind, placebo-controlled, dose-optimization study, with participants in 59 study sites who continued their stable dose of psychostimulant given in the morning and were randomized to receive GXR in the morning, GXR in the evening, or placebo.
For both morning and evening administration of GXR, subjects receiving GXR plus a psychostimulant showed significantly greater improvement from baseline to endpoint, as measured by the ADHD-Rating Scale IV total score, compared with subjects receiving placebo plus a psychostimulant. In particular, the inattention subscale rating and the hyperactivity/ impulsivity subscales of the ADHD-RS-IV showed significantly greater improvements from baseline in subjects receiving GXR with a psychostimulant compared with subjects receiving placebo plus psychostimulant. Significant benefits of adjunctive administration were observed whether GXR was administered in the morning or evening. No new safety signals emerged after adjunctive administration of GXR with psychostimulants compared with psychostimulants alone.
Reflecting on their research findings, Wilens and colleagues stated, "The results of this study support the hypothesis that adjunctive administration of the selective alpha2A-adrenoceptoragonist, GXR, to a psychostimulant in subjects with suboptimal response to psychostimulants reduces ADHD symptoms over placebo with a psychostimulant."
###
The article is "A Controlled Trial of Extended-release Guanfacine and Psychostimulants for Attention-deficit/hyperactivity disorder" by Timothy E. Wilens, Oscar Bukstein, Matthew Brams, Andrew J. Cutler, Ann Childress, Thomas Rugino, Andrew Lyne, Kara Grannis, Sharon Youcha (doi:10.1016/j.jaac.2011.10.012). The article appears in Journal of the American Academy of Child and Adolescent Psychiatry, Volume 51, Issue 1 (January 2012), published by Elsevier.
This study was supported by Shire Development Inc., Wayne, PA.
Notes for editors
Full text of the article is available to credentialed journalists upon request; contact Mary Billingsley at +1 202 966 7300 x105 or mbillingsley@jaacap.org. Journalists wishing to interview the authors may contact Dr. Timothy E. Wilens at twilens@partners.org.
About JAACAP
Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP) is the official publication of the American Academy of Child and Adolescent Psychiatry. JAACAP is the leading journal focusing exclusively on today's psychiatric research and treatment of the child and adolescent. Published twelve times per year, each issue is committed to its mission of advancing the science of pediatric mental health and promoting the care of youth and their families.
The journal's purpose is to advance research, clinical practice, and theory in child and adolescent psychiatry. It is interested in manuscripts from diverse viewpoints, including genetic, epidemiological, neurobiological, cognitive, behavioral, psychodynamic, social, cultural, and economic. Studies of diagnostic reliability and validity, psychotherapeutic and psychopharmacological treatment efficacy, and mental health services effectiveness are encouraged. The journal also seeks to promote the well-being of children and families by publishing scholarly papers on such subjects as health policy, legislation, advocacy, culture and society, and service provision as they pertain to the mental health of children and families.
About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV; the combined market capitalization of the two parent companies is approximately £12bn/€13bn. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact
Mary Billingsley
Editorial Office JAACAP
+1 202 966 7300 x105
mbillingsley@jaacap.org
END
Thermonuclear fusion promises to be a possible solution to the current energy crisis. It is produced when two atomic nuclei of light elements combine to produce heavier elements, which give off a huge quantity of energy. So that this reaction can occur, it is necessary to supply an enormous amount of energy, so that temperatures of many millions of degrees can be reached, allowing the nuclei to come close enough to overcome their natural repulsion and become condensed in a plasma state. "This plasma, which reaches temperatures near that of the stars, around 100 million ...
As an embryo develops, different genes are turned on in different cells, to form muscles, neurons and other bodily parts. Inside each cell's nucleus, genetic sequences known as enhancers act like remote controls, switching genes on and off. Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, can now see – and predict – exactly when each remote control is itself activated, in a real embryo. Their work is published today in Nature Genetics.
Stefan Bonn, Robert Zinzen and Charles Girardot, all in Eileen Furlong's lab at EMBL, found that ...
RealCapitalMarkets.com, LLC (RCM1), the leading provider of a leading provider of marketing and transaction management software for commercial property and note sales, announces updates to the RCM1 platform designed to extend client control, enhance mobile support, and expand data integration with client customer relationship management (CRM) systems.
"We are consistently developing new tools to allow our clients to more efficiently sell commercial real estate assets and stay ahead of their competition," said Tina Lichens, RCM1's COO. "This release is ...
A great assistant software has just launched that would be helpful for completing the computer room maintenance effectively.
PC Network Clone 5.0 is a Windows application for massive hard drive cloning and system installation. It's designed to deploy computer systems and applications for hundreds or even thousands of computers over Local Area Network.
The various features of PC Network Clone 5.0 are thus hereby listed below:
Runs on Windows System and Supports Windows 7 / Vista / XP / Server 2008, both for 32bit and 64bit.
PC Network Clone 5.0 is compatible ...
A Rush University Medical Center led international research team has announced that a treatment to prevent bleeding episodes in children with hemophilia A also is effective for adolescents and adults.
The preventive therapy will "optimize care for hemophilia patients of all ages by stopping unexpected bleeding events that can have a detrimental impact on the lives of patients," said Dr. Leonard Valentino, director of the Rush Hemophilia and Thrombophilia Center and principal investigator on the study. The study results appeared in the January online version of the Journal ...
DURHAM, N.C. – Tuning in to tune out may be just what's needed for men undergoing a prostate biopsy, according to researchers at the Duke Cancer Institute.
The Duke team found that noise-cancelling headphones playing a classical melody may reduce the pain and anxiety of the often uncomfortable procedure.
The finding, published this month in the journal Urology, points to a simple and inexpensive way to help an estimated 700,000 U.S. men who undergo a prostate biopsy a year. The procedure is essentially the only way to diagnose prostate cancer, which strikes one in six ...
COLUMBIA, Mo. – As the U.S. economy continues to lag, many investors remain wary about taking risks with the stock market. Now, researchers at the University of Missouri have concluded that this attitude toward investment risk-taking is influenced by the age of the investor and the economic climate of the time period. Rui Yao, an assistant professor of personal financial planning in the College of Human Environmental Sciences at MU, found that willingness to take financial risks, or "risk tolerance," decreases as investors age.
"Age has a pragmatic relationship with financial ...
New York / Heidelberg, 9 January 2012 -- Young female cancer survivors are concerned about their future fertility and parenthood options and want better information and guidance early on, according to a new study by Jessica Gorman and her team from the University of California in the US. Their paper, which presents in-depth information on young survivors' experiences navigating decisions about fertility and parenthood, is published online in Springer's Journal of Cancer Survivorship.
Many more adolescents and young adults are surviving their disease, resulting in a substantial ...
Philadelphia, January 9, 2012 – In the first study to investigate driving as it relates to teens with a high-functioning autism disorder (HFASD), child development and teen driving experts at The Children's Hospital of Philadelphia's Center for Child Injury Prevention Studies found that two-thirds of teenagers with a high-functioning autism spectrum disorder (HFASD) who are of legal driving age in their state are currently driving or plan to drive.
The study is published this month in the Journal of Developmental and Behavioral Pediatrics.
A HFASD is characterized ...
Miguel A. Cazalilla, a scientist at the CFM (a joint CSIC-UPV/EHU center) and the Donostia International Physics Center (DIPC), together with other four colleagues from various institutions in Europe and the United States, was recently invited to write a review article that has been just published in the prestigious journal Reviews of Modern Physics of the American Physical Society, where only leading scientists in their field of physics are invited to contribute. The article, "One dimensional Bosons: From Condensed Matter to Ultracold Atoms", offers a glimpse into the ...
